Abstract
A novel series of N-aryl-N'-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound 1h (NVP-BGJ398) was selected for in vivo evaluation and showed significant antitumor activity in RT112 bladder cancer xenografts models overexpressing wild-type FGFR3. These results support the potential therapeutic use of 1h as a new anticancer agent.
MeSH terms
-
Angiogenesis Inhibitors / chemical synthesis
-
Angiogenesis Inhibitors / pharmacokinetics
-
Angiogenesis Inhibitors / pharmacology
-
Animals
-
Antineoplastic Agents / chemical synthesis*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Crystallography, X-Ray
-
Drug Screening Assays, Antitumor
-
Female
-
Humans
-
Mice
-
Mice, Nude
-
Models, Molecular
-
Neoplasm Transplantation
-
Phenylurea Compounds / chemical synthesis*
-
Phenylurea Compounds / pharmacokinetics
-
Phenylurea Compounds / pharmacology
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / pharmacokinetics
-
Pyrimidines / pharmacology
-
Rats
-
Rats, Wistar
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
-
Receptor, Fibroblast Growth Factor, Type 3 / antagonists & inhibitors
-
Receptors, Fibroblast Growth Factor / antagonists & inhibitors*
-
Structure-Activity Relationship
-
Transplantation, Heterologous
-
Urinary Bladder Neoplasms
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Phenylurea Compounds
-
Pyrimidines
-
Receptors, Fibroblast Growth Factor
-
infigratinib
-
Receptor Protein-Tyrosine Kinases
-
Receptor, Fibroblast Growth Factor, Type 3